Everything below concerns cyclic heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-24. Numbers and descriptions here follow the published literature rather than marketing material.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic cyclic heptapeptide | Analog of alpha-MSH with an internal lactam bridge |
| Molecular weight | Approximately 1024 daltons | Free base value; salt forms differ |
| Appearance | White to off-white powder | Usually supplied as a lyophilized solid |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar solvents |
| Typical storage | −20 °C, dry, protected from light | Repeated freeze-thaw cycles degrade peptides |
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
PAHs, subjected to interstellar medium (ISM) conditions, are transformed, through hydrogenation, oxygenation, and hydroxylation, to more complex organic compounds—"a step along the path toward amino acids and nucleotides, the raw materials of proteins and DNA, respectively". Further, as a result of these transformations, the PAHs lose their spectroscopic signature which could be one of the reasons "for the lack of PAH detection in interstellar ice grains, particularly the outer regions of cold, dense clouds or the upper molecular layers of protoplanetary disks." Low-temperature chemical pathways from simple organic compounds to complex PAHs are of interest. Such chemical pathways may help explain the presence of PAHs in the low-temperature atmosphere of Saturn's moon Titan, and may be significant pathways, in terms of the PAH world hypothesis, in producing precursors to biochemicals related to life as we know it.
On 21 July, the Syrian Observatory for Human Rights said that nine civilians were injured by a drone attack on the city of Shahba by Bedouin tribes. On 25 July, the Syrian Observatory for Human Rights reported ceasefire violations in Umm al-Zaytoun village and areas of Reema Hazem and in Walgha. Tensions persisted in the Kanaker region with the presence of tribal gunmen. On 26 July, the spiritual leadership of the Druze, headed by Sheikh Hikmat al-Hijri, announced the formation of a "Supreme Legal Committee" consisting of six judges, including four judicial advisors, and three lawyers. The committee outlined its responsibilities as managing public affairs across all sectors in Suwayda, including administrative, security, and service-related matters.
The suit also alleged that Theranos had misled company directors about its practices concerning laboratory testing and that it had secretly bought lab equipment to run fake demonstrations. On May 1, 2017, Theranos announced that it had reached an undisclosed settlement with Partner Fund Management LP (PFM). Theranos's General Counsel, David Taylor, stated: "Theranos is pleased to have resolved both lawsuits with PFM. Although we are confident that we would have prevailed at trial, resolution of these two cases allows our tender offer to go forward and enables us to return our focus where it belongs, which is on executing our business plans and delivering value for our shareholders." In April 2017, Theranos reached a settlement with CMS agreeing to stay out of the blood-testing business for at least two years in exchange for reduced penalties, and signed a consent decree with Arizona Attorney General Mark Brnovich over violations of the Arizona Consumer Fraud Act. Alleged violations included false advertisement and inaccurate blood testing. Theranos agreed to refund $4.65 million to the state's residents for Theranos blood testing services, providing a refund to every resident who had received a test, regardless of whether the test results were voided or corrected. In August 2017, Theranos announced it had reached a settlement with Walgreens. In December 2017, Fortress Investment Group, a wholly owned company of Softbank Group, loaned $100 million to Theranos for 4% of the company.
Schröder (1993, 2002) reviewed the issue of CPA dosage and recommended a dosage of 200 to 300 mg/day for CPA as a monotherapy and a dosage of 100 to 200 mg/day for CPA in combined androgen blockade (that is, CPA in combination with surgical or medical castration). However, the combination of CPA with castration for prostate cancer has been found to significantly decrease overall survival compared to castration alone. Hence, the use of CPA as the antiandrogen component in combined androgen blockade would appear not to be advisable. When used by intramuscular injection to treat prostate cancer, CPA is used at a dosage of 300 mg once a week. The combination of CPA with an estrogen such as ethinylestradiol sulfonate or low-dose diethylstilbestrol has been used as a form of combined androgen blockade and as an alternative to the combination of CPA with surgical or medical castration.
Sources: en.wikipedia.org
When allowed to react with superacids, sulfuric acid can act as a base and can be protonated, forming the [H3SO4]+ ion. Salts of [H3SO4]+ have been prepared (e.g. trihydroxyoxosulfonium hexafluoroantimonate(V) [H3SO4]+[SbF6]−) using the following reaction in liquid HF:
While the Rockefeller doctors working in tropical locales such as Mexico emphasized scientific neutrality, they had political and economic aims to promote the value of public health to improve American relations with the host country. Although they claimed the banner of public health and humanitarian medicine, they often engaged with politics and business interests. Rhoads was involved in a racism whitewashing scandal in the 1930s during which he joked about injecting cancer cells into Puerto Rican patients, inspiring Puerto Rican nationalist and anti-colonialist leader Pedro Albizu Campos. Noguchi was also involved in an unethical human experimentation scandal. Susan Lederer, Elizabeth Fee, and Jay Katz are among the modern scholars who have researched this period. Researchers with the foundation including Noguchi developed the vaccine to prevent yellow fever. Rhoads later became a significant cancer researcher and director of Memorial Sloan-Kettering, though his eponymous award for oncological excellence was renamed after the scandal reemerged.
=== 1980s === 1982: Nephrologist Leah Lowenstein became the first woman dean of a co-educational medical school in the United States. 1983: Barbara McClintock received the Nobel Prize in Physiology or Medicine for her discovery of genetic transposition; she was the first woman to receive that prize without sharing it, and the first American woman to receive any unshared Nobel Prize. 1984: Kathryn D. Sullivan becomes the first American woman to walk in space. 1988: Patricia Bath was the first African American woman to receive a medical patent, which was her invention of laser cataract treatment. 1988: Gertrude B. Elion received the Nobel Prize in Physiology or Medicine along with James W. Black and George H. Hitchings "for their discoveries of important principles for drug treatment".
== Further reading == A. Abragam (1961). The Principles of Nuclear Magnetism. Clarendon Press. ISBN 978-0-19-852014-6. {{cite book}}: ISBN / Date incompatibility (help) J.W. Akitt; B.E. Mann (2000). NMR and Chemistry. Cheltenham, UK: Stanley Thornes. pp. 273, 287. ISBN 978-0-7487-4344-5. K.V.R. Chary, Girjesh Govil (2008) NMR in Biological Systems: From Molecules to Human. Springer. ISBN 978-1-4020-6680-1. G.M. Clore; A.M. Gronenborn (1991). "Structures of larger proteins in solution: three- and four-dimensional heteronuclear NMR spectroscopy". Science. 252 (5011): 1390–1399. Bibcode:1991Sci...252.1390M. doi:10.1126/science.2047852. OSTI 83376. PMID 2047852. John Emsley; James Feeney; Leslie Howard Sutcliffe (1965). High Resolution Nuclear Magnetic Resonance Spectroscopy. Pergamon. ISBN 978-1-4831-8408-1. The Feynman Lectures on Physics Vol. II Ch. 35: Paramagnetism and Magnetic Resonance David M. Grant; Robin Kingsley Harris (2002). "Advances in NMR". Encyclopedia of Nuclear Magnetic Resonance. John Wiley. ISBN 978-0-471-49082-1. R.L. Haner; P.A. Keifer (2009). "Flow Probes for NMR Spectroscopy". Encyclopedia of Magnetic Resonance. John Wiley. doi:10.1002/9780470034590.emrstm1085. ISBN 978-0-470-03459-0. J.P. Hornak. "The Basics of NMR". Retrieved 23 February 2009. J. Keeler (2005). Understanding NMR Spectroscopy. John Wiley & Sons. ISBN 978-0-470-01786-9. Gary E. Martin; A. S. Zektzer (1988). Two-Dimensional NMR Methods for Establishing Molecular Connectivity. New York: Wiley-VCH. p. 59. ISBN 978-0-471-18707-3. J.A.Pople; W.G.Schneider; H.J.Bernstein (1959).
Corticosteroids: Produced by the adrenal cortex, these hormones regulate stress responses, electrolyte balance, and immune function. Glucocorticoids: Involved in carbohydrate metabolism, anti-inflammatory actions, and immunosuppression. Cortisol, which increases blood glucose levels during stress and suppresses immune activity to prevent excessive inflammation. Mineralocorticoids: Control salt and water balance to maintain blood pressure. Aldosterone, which promotes sodium reabsorption in the kidneys, thereby regulating extracellular fluid volume. Sex steroids: Derived mainly from the gonads and adrenal glands, these influence sexual development, reproduction, and secondary sexual characteristics. Progestogens: Essential for preparing the reproductive system for pregnancy. Progesterone, which supports implantation and sustains early pregnancy by maintaining the uterine lining. Androgens: Promote male reproductive development and maintenance. Testosterone, which drives spermatogenesis and the growth of male secondary sex characteristics such as muscle mass and facial hair. Estrogens: Key to female reproductive cycles and skeletal health. Estradiol, which stimulates endometrial proliferation during the menstrual cycle and contributes to bone density. Other steroids extend beyond hormonal roles and include compounds involved in neuroprotection, digestion, and neuromuscular activity:
Sources: en.wikipedia.org
==== Establishing immunity ==== Part of the kitten's immune system is the mucosal immune system, which is within the gastrointestinal tract. The mucosal immune system is largely responsible for coordinating proper immune responses by tolerating innocuous antigens and attacking foreign pathogens. In order to optimize kitten health and increase chances of survival, it is important to optimize the link between the gut-associated lymphoid tissue and the microbiota of the gastrointestinal tract. Lasting health and longevity can be promoted partly through proper nutrition, as well as by establishing a healthy gut from birth through the use of colostrum.
The extent to which psilocin (and by extension psilocybin) is metabolized by MAO, specifically MAO-A, is not fully clear, but has ranged from 4% to 33% in different studies based on metabolite excretion. However, circulating levels of the deaminated metabolite of psilocin are far higher than those of free unmetabolized psilocin with psilocybin administration. An early clinical study of psilocybin in combination with short-term tranylcypromine pretreatment found that tranylcypromine marginally potentiated the peripheral effects of psilocybin, including pressor effects and mydriasis, but overall did not significantly modify the psychoactive and hallucinogenic effects of the psilocybin, although some of its emotional effects were said to be reduced and some of its perceptual effects were said to be amplified. Some psychedelics are substrates of cytochrome P450 (CYP450) enzymes, for instance LSD being a substrate of CYP2D6 as well as of several other CYP450 enzymes. As such, CYP450 inhibitors may increase exposure to CYP450-substrate psychedelics such as LSD and thereby potentiate their effects as well as risks. A clinical study found that administration of LSD to people taking paroxetine, a selective serotonin reuptake inhibitor (SSRI) and strong CYP2D6 inhibitor, increased LSD exposure by about 1.5-fold. The combination was well-tolerated and did not modify the pleasant subjective effects or physiological effects of LSD, whereas negative effects of LSD, including "bad drug effect", anxiety, and nausea, were reduced.
=== Filming === Initial film shooting started in February 1992 through to April 1992. Film producers were reluctant to release too much information about the film to the media, particularly the ending, while photograph releases to print media were limited. Various locations were used including Mendocino County where shooting took place from March 29 to April 2. A purpose-built set was built at the Stornetta Ranch, near the lighthouse in Point Arena. Although the film made use of real rain for some exterior scenes, artificial rainmakers were also used to maintain a consistency in downpours for the cameras. Curtis had never met Gibson prior to working with him on the film. During an interview, she notes the cast members would frequently play pranks on each other but that "it was a fun set, this was the fun place to be." It was the first film where Curtis had played a mother. Gibson had to spend 2 hours each day to have the latex aging make-up applied to make him appear as an 80-year-old. During filming, he slipped and dislocated his shoulder, but did not immediately realize the severity of the injury. After becoming dizzy and struggling to remember his lines, a chiropractor reset his shoulder. Gibson later remarked that forgetting his lines troubled him more than the pain. In the scene where Wood sings "You Are My Sunshine" to the girl in the tree house, it was originally going to be a different song which according to director Steve Miner, would have been very expensive to use, whereas the song used in the film was already freely available in the public domain.
Like all proteins, the unique amino acid arrangement in the primary sequence of GLUT4 is what allows it to transport glucose across the plasma membrane. In addition to the phenylalanine on the N-terminus, two Leucine residues and acidic motifs on the COOH-terminus are believed to play a key role in the kinetics of endocytosis and exocytosis.
In order to successfully complete their folding, both actin and tubulin need to interact with another protein called prefoldin, which is a heterohexameric complex (formed by six distinct subunits), in an interaction that is so specific that the molecules have coevolved. Actin forms a complex with prefoldin while it is still being formed, when it is approximately 145 amino acids long, specifically those at the N-terminal. Different recognition sub-units are used for actin or tubulin although there is some overlap. In actin the subunits that bind with prefoldin are probably PFD3 and PFD4, which bind in two places one between residues 60–79 and the other between residues 170–198. The actin is recognized, loaded, and delivered to the cytosolic chaperonin (CCT) in an open conformation by the inner end of prefoldin's "tentacles" (see the image and note). The contact when actin is delivered is so brief that a tertiary complex is not formed, immediately freeing the prefoldin.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.
Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.
No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.